TBRG4 promotes hepatocellular carcinoma progression by inhibiting ferroptosis through the DDX56/p-AKT/GSK3β pathway and binding to Beclin1, while its knockdown reduces tumor cell proliferation, migration, and invasion. Here, AKT1 is linked to hepatocellular carcinoma.